A prospective observational study of immune-related adverse events, treatment efficacy, and pre-existing autoantibodies in patients with small-cell lung cancer who was treated by immune checkpoint inhibitor

A prospective observational study of immune-related adverse events, treatment efficacy, and pre-existing autoantibodies in patients with small-cell lung cancer who was treated by immune checkpoint inhibitor - Pre-existing autoantibodies and irAE in SCLC patients treated with ICI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042962

Enrollment

Registered

2021-01-15

Start date

2019-08-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with small cell lung cancer who was treated by chemotherapy plus immune checkpoint inhibitor as first line therapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as small-cell lung cancer, who was treated by chemotherapy plus immune checkpoint inhibitor Patients over 20 years old Patients who provided written informed consent before enrolment

Exclusion criteria

Exclusion criteria: Patients who were determined as unsuitable by attending physician

Design outcomes

Primary

Measure	Time frame
the incidence of immune-related adverse events	—

Secondary

Measure	Time frame
The incidence of paraneoplastic syndrome Progression free survival Overall survival	—

Countries

Japan

Contacts

Public ContactYuki Sato

Kobe City Medical Center General Hospital Respiratory Medicine

yuki_sato@kcho.jp0783024321

Outcome results